• How Fasting Rewires Translation to Drive Ketogenesis

  2026-09-23

  Yang and colleagues show that fasting can reduce global protein synthesis while selectively increasing translation of liver mRNAs needed for lipid catabolism and ketone production. Their work identifies a fatty-acid–AMPK–MNK–P-eIF4E pathway and finds that inhibiting P-eIF4E during a ketogenic diet can restrain pancreatic tumor growth in the tested model.

• AG-120 (Ivosidenib) Workflows for IDH1 Research

  2026-09-23

  Build a mechanism-first workflow with AG-120 (Ivosidenib) that links mutant IDH1 inhibition to 2-hydroxyglutarate reduction, metabolic rewiring, and differentiation phenotypes. The approach combines metabolite, viability, and myeloid readouts to improve interpretation in AML models and ex vivo samples.

• From CTD Phosphorylation to Cysteine Accessibility

  2026-09-22

  A translational framework connecting RNA polymerase II CTD phosphorylation, chemical-proteomic validation, and MTSEA-biotin as a practical tool for testing protein accessibility and regulatory mechanism.

• ARCA EGFP mRNA for Transfection Workflows

  2026-09-22

  ARCA EGFP mRNA provides a fast, direct fluorescence readout for separating delivery performance from downstream protein expression in mammalian cells. Its ARCA cap and approximately 100-nucleotide poly(A) tail make it a practical control for lipid nanoparticle benchmarking, transfection optimization, and early-stage assay development.

• Diphenyleneiodonium chloride Workflow Guide

  2026-09-21

  Diphenyleneiodonium chloride enables side-by-side interrogation of oxidase-linked ROS and GPR3-associated cAMP responses, but its broad target profile demands careful controls. This workflow translates a recent citrus canker study into practical redox, ferroptosis-oriented, and cell-signaling assay strategies.

• Repaglinide and the Energy–DNA Repair Axis

  2026-09-21

  Energy deficiency can reshape DNA repair through ATG4B nuclear translocation and disruption of PRMT1-dependent MRE11 regulation in acute myeloid leukemia. This article positions Repaglinide as a carefully bounded metabolic-context perturbation for translational studies—not as a validated ATG4B inhibitor or leukemia treatment—and outlines how to build a rigorous workflow around that distinction.

• Isoproterenol Sulfate Dihydrate in SAN Research

  2026-09-20

  Isoproterenol sulfate dihydrate provides a controllable acute stimulus for beta-adrenergic receptor signaling in human SAN-plexus assembloids. Used alongside electrophysiology, calcium imaging, and neural co-culture comparisons, it helps distinguish intrinsic pacemaker maturation from reversible sympathetic-like modulation.

• AG-120 and the Metabolic Logic of IDH1 AML

  2026-09-19

  AG-120 (Ivosidenib) translates mutant IDH1 biology into a measurable differentiation strategy for AML research. By connecting 2-hydroxyglutarate reduction with CD44-mediated metabolic rewiring, this article outlines how translational teams can design stronger pharmacodynamic, resistance, and combination studies.

• From Interaction Maps to Translational Decisions

  2026-09-18

  Protein interaction data become valuable when they change a biological or development decision. This thought-leadership article connects the genomic and field findings from a recent Trichoderma–peanut study with practical strategies for validating candidate protein partners. It explains how Fc capture, magnetic separation, controls, elution choices, and orthogonal confirmation can turn a co-IP experiment into a defensible evidence chain. The Protein A/G Magnetic Co-IP/IP Kit is presented not as a substitute for experimental design, but as a standardized capture layer for moving from candidate discovery to mechanistic confidence.

• (R)-MG132 for Causal Proteasome Assays

  2026-09-18

  (R)-MG132 is an inactive MG-132 enantiomer for separating proteasome-dependent effects from solvent, cytotoxic, and off-target responses. This article presents a causal assay framework linking stereochemical controls to HNRNPU lactylation and serine-metabolism studies.

• Tamoxifen Workflows for Cancer and CreER Research

  2026-09-17

  Tamoxifen supports both established estrogen-receptor studies and newer immune-oncology workflows that pair macrophage reprogramming with radiotherapy. This guide translates those use cases into practical preparation, assay-design, CreER controls, and troubleshooting strategies.

• Chloroquine Diphosphate in Ferroptosis Assays

  2026-09-17

  Chloroquine Diphosphate can function as an orthogonal autophagy and lysosomal perturbation tool in AML ferroptosis research. This article translates ACSL4–DGLA findings into assay design, interpretation, and controls without confusing autophagy modulation with proof of ferroptotic death.

• Ether Lipids Shape B Cell Antibody Responses

  2026-09-16

  This reference study establishes a causal link between B-cell-intrinsic ether lipid biosynthesis and the magnitude, affinity maturation, and germinal-center development of antibody responses. By combining inducible Dhrs7b loss-of-function models with imaging mass spectrometry, immunization, and cellular assays, it identifies PexRAP-dependent control of oxidative stress and membrane peroxidation as a mechanism supporting B-cell survival.

• Hoechst 33342/PI Double Staining Kit Guide

  2026-09-16

  The Hoechst 33342/PI Double Staining Kit (K2237) provides a two-color microscopy workflow for comparing nuclear chromatin changes with loss of membrane integrity in cell death studies. It is intended for scientific research, not diagnostic or medical use, and should be interpreted with appropriate controls rather than as a standalone classification method.

• Anlotinib Hydrochloride: Anti-Angiogenic TKI

  2026-09-15

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor with potent anti-angiogenic activity centered on VEGFR2, PDGFRβ, and FGFR1. Preclinical evidence supports its use in endothelial migration, capillary tube formation, receptor-phosphorylation, and cancer research workflows, while remaining distinct from clinical efficacy evidence.

8598 records 1/574 page Next 12345 下5页 Last page